Acadia Pharmaceuticals (ACAD) Other Non-Current Liabilities (2010 - 2026)

Acadia Pharmaceuticals' Other Non-Current Liabilities history runs 11 years deep, the most recent figure standing at $12.6 million for Q1 2026.

• In Q1 2026, Other Non-Current Liabilities fell 36.7% year-over-year to $12.6 million; the TTM figure through Mar 2026 stood at $12.6 million (down 36.7% YoY), while the FY2025 annual figure was $19.1 million, up 5.99% from the prior year.
• Other Non-Current Liabilities was $12.6 million for Q1 2026 at Acadia Pharmaceuticals, down from $19.1 million in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $28.5 million in Q2 2025 to a low of $4.4 million in Q1 2022.
• Historically, Other Non-Current Liabilities has averaged $12.9 million across 5 years, with a median of $12.6 million in 2026.
• The sharpest annual moves came in 2025 and 2026: Other Non-Current Liabilities soared 130.93% in 2025, then slumped 36.7% in 2026.
• A 5-year view of Other Non-Current Liabilities shows it stood at $9.1 million in 2022, then jumped by 66.93% to $15.1 million in 2023, then climbed by 19.21% to $18.1 million in 2024, then climbed by 5.99% to $19.1 million in 2025, then slumped by 33.97% to $12.6 million in 2026.
• The last three Other Non-Current Liabilities figures came in at $12.6 million (Q1 2026), $19.1 million (Q4 2025), and $13.9 million (Q3 2025), per Business Quant data.